Current Report Filing (8-k)
11 August 2022 - 10:06PM
Edgar (US Regulatory)
0001173281
false
0001173281
2022-08-11
2022-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
August 11, 2022
NeuBase Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
| Delaware |
|
001-35963 |
|
46-5622433 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
| 350 Technology Drive,
Pittsburgh,
PA |
|
15219 |
| (Address
of Principal Executive Offices) |
|
(Zip Code) |
| |
(412)
763-3350 |
|
| |
(Registrant’s
Telephone Number, Including Area Code) |
|
| |
N/A |
|
| |
(Former
Name or Former Address, if Changed Since Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
NBSE |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act
of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02. |
Results of Operations and Financial Condition. |
On August 11, 2022, NeuBase Therapeutics, Inc. (the “Company”)
issued a press release announcing its financial results for the fiscal quarter ended June 30, 2022, and provided a corporate update. A
copy of the press release is furnished as Exhibit 99.1 to this Current Report.
In accordance with General Instructions B.2 of Form 8-K, the information
in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated
by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
NEUBASE THERAPEUTICS, INC. |
| |
(Registrant) |
| |
|
| Date: August 11, 2022 |
By: |
/s/ Todd P. Branning |
| |
|
Todd P. Branning |
| |
|
Chief Financial Officer |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Oct 2024 to Nov 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Nov 2023 to Nov 2024
